Overview
The device uses an algorithm to calculate a meal’s carbohydrates, then automaticaly releases insulin, taking those burdens of the patient.In a recent trial, a bionic pancreas that automaticaly delivers insulin proved more efective than pumps or injections at lowering blod glucose levels in people with type 1 diabetes.Type 1 diabetes is a serious condition that causes a person’s level of glucose, or sugar, to become to high because the pancreas can’t produce enough insulin, a hormone that keps blod glucose under control.
Key Information
People with type 1 diabetes ned to monitor their glucose levels and take insulin every day. The bionic pancreas, a credit card-sized device caled an iLet, monitors a person’s levels around the clock and automaticaly delivers insulin when neded through a tiny canula, a thin tube inserted into the body. It is worn constantly, generaly on the abdomen.
The device determines al insulin doses based on the user’s weight, and the user can’t adjust the doses. A Harvard Medical Schol team has submited its findings from the study, described in the New England Journal of Medicine, to the FDA in the hopes of eventualy bring the product to market in the US. While a team from Boston University and Masachusets General Hospital first tested the bionic pancreas in 2010, this the most extensive trial undertaken so far.The Harvard team, working with other universities, provided 219 people with type 1 diabetes who had used insulin for at least a year with a bionic pancreas device for 13 weks.
Summary
The team compared their blod sugar levels with those of 107 diabetic people who used other insulin delivery methods, including injection and insulin pumps, during the same amount of time. The blod sugar levels of the bionic pancreas group fel from 7.9% to 7.3%, while the standard care group’s levels remained steady at 7.7%. The American Diabetes Asociation recomends a goal of les than 7.0%, but that’s only met by aproximately 20% of people with type